Intraperitoneal and subcutaneous glucagon delivery in anaesthetized pigs: effects on circulating glucagon and glucose levels. 2020

Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Postboks 8905, 7491, Trondheim, Norway. marte.k.am@ntnu.no.

Glucagon is a pancreatic hormone and increases the blood glucose levels. It may be incorporated in a dual hormone artificial pancreas, a device to automatically and continuously control blood glucose levels of individuals with diabetes. Artificial pancreas systems have been developed for use in the subcutaneous tissue; however, the systems are not fully automated due to slow dynamics. The intraperitoneal space is therefore investigated as an alternative location for an artificial pancreas. Glucose dynamics after subcutaneous and intraperitoneal glucagon delivery in ten anaesthetized pigs were investigated. The pigs received intraperitoneal boluses of 0.3 µg/kg and 0.6 µg/kg and a subcutaneous bolus of 0.6 µg/kg in randomized order. They also received an intraperitoneal bolus of 1 mg given at the end of the experiments to test the remaining capacity of rapid glucose release. Six pigs were included in the statistical analysis. The intraperitoneal glucagon bolus of 0.6 µg/kg gave a significantly higher glucose response from 14 to 30 min compared with the subcutaneous bolus. The results indicate that glucagon induces a larger glucose response after intraperitoneal delivery compared with subcutaneous delivery and is encouraging for the incorporation of glucagon in an intraperitoneal artificial pancreas.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D019397 Pancreas, Artificial Devices for simulating the activity of the pancreas. They can be either electromechanical, consisting of a glucose sensor, computer, and insulin pump or bioartificial, consisting of isolated islets of Langerhans in an artificial membrane. Artificial Pancreas

Related Publications

Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
May 1981, Diabetologia,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
January 2024, Current therapeutic research, clinical and experimental,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
September 1997, The American journal of physiology,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
September 2009, Diabetes/metabolism research and reviews,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
August 2000, Metabolism: clinical and experimental,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
July 1979, Diabetologia,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
November 2000, Metabolism: clinical and experimental,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
November 1996, Diabetes care,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
March 1976, Endocrinology,
Marte Kierulf Åm, and Ilze Dirnena-Fusini, and Anders Lyngvi Fougner, and Sven Magnus Carlsen, and Sverre Christian Christiansen
January 1985, Drugs under experimental and clinical research,
Copied contents to your clipboard!